1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1422 articles with Genentech, Inc.
Genentech’s Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer
IMpassion031 data will be discussed with health authorities globally, including the U.S. Food and Drug Administration and the European Medicines Agency
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
6/15/2020It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Positive Phase III Results for Venclexta Combination in Acute Myeloid Leukemia Presented At EHA 2020
Phase III VIALE-A study showed Venclexta plus azacitidine helped people with the most common type of aggressive adult leukemia live longer compared to azacitidine alone – – Data will be presented as a late-breaking abstract at the 25th European Hematology Association Virtual Congress –
Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults With Spinal Muscular Atrophy (SMA)
SUNFISH Part 1 showed risdiplam significantly improved motor function after 24 months of treatment in people aged 2-25 years with Types 2 or 3 SMA – – JEWELFISH study preliminary 12-month data in previously treated patients showed rapid and sustained increases in SMN protein levels trial – – Safety was consistent with the safety profile observed to date and no new safety signals were identified – SOUTH SAN FRANCISCO, Calif.--( BUSINESS
6/8/2020As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.
Tecentriq is an anti-PD-L1 checkpoint inhibitor. Avastin binds to the VEGF protein, which plays a significant role in the development and maintenance of blood vessels by cancer cells.
The American Society of Clinical Oncology 2020 meeting was held virtually this year due to the COVID-19 pandemic. As usual, there were literally hundreds of abstracts, posters and presentations. Here’s a look at some of the highlights.
FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Numerous biopharmaceutical companies and researchers are presenting research and clinical trial results, and many have been announcing their plans for several weeks.
Genentech Initiates Phase III Clinical Trial of Actemra Plus Remdesivir in Hospitalized Patients With Severe COVID-19 Pneumonia
Genentech is also close to completing enrollment of a global randomized, double-blind, placebo-controlled Phase III clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia (COVACTA), with results expected this summer
Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degeneration
Genentech, a member of the Roche Group announced positive topline results from the Phase III Archway study, evaluating Port Delivery System with ranibizumab in people living with neovascular or “wet” age-related macular degeneration.
Genentech announced on Wednesday that it has seen positive topline results from Archway, its Phase III study looking into its Port Delivery System (PDS) with ranibizumab for the treatment of neovascular or “wet” age-related macular degeneration.
Since COVID-19 began its sweep across the United States, data has shown the disease caused by the novel coronavirus has disproportionately impacted racial and ethnic minority groups across the country.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 27, 2020.
New Longer-Term Data Reinforce Safety of Genentech’s Satralizumab in Adults and Adolescents With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD)
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
The approval was based on interim analysis from the company’s Phase III IMpower110 trial.
Flatiron Health, Foundation Medicine and Genentech Partner to Launch Novel Prospective Lung Cancer Clinical Study
The Prospective Clinico-Genomic Study aims to understand the cancer patient journey at scale by linking real-world clinical outcomes with genomic data, clinical images, and digital pathology data NEW YORK--( BUSINESS WIRE )-- Flatiron Health, Foundation Medicine, and Genentech, a member of the Roche Group, in partnership with community and academic oncology practices, have launched the Prospective Clinico-Genomic (PCG) Study, NCT04180176 . PCG is a n
FDA Approves Genentech’s Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer
Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy